| Name | Title | Contact Details |
|---|
At Intouch Solutions, we know pharma marketing isn`t easy. But after more than a decade of hard work in this and similarly regulated industries, we think we understand that better than most. We have a pretty good idea of what it takes to connect your customers to your brand.
Imagine Pharma is a drug discovery and development company that focuses on innovative approaches to therapeutic drugs for diabetes and cardiovascular disease. Our agile, creative and efficient approach to drug discovery is designed to find therapeutics that significantly improve on the efficacy and safety of existing treatments.
XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.
Aspyrian Therapeutics is a new start-up located in San Diego (California, USA) that focuses on developing novel targeted therapies for Oncology, Inflammation, and Pain. Aspyrian Therapeutics and its collaborators are developing novel cancer targeted therapies based on proprietary technologies that achieve highly specific and tumor restricted anticancer activity. Tumor specific action serves to avoid damage to healthy organs for enhanced anticancer activity and increased safety profile. Aspyrian Therapeutics has secured the exclusive license from the National Cancer Institute for a new Antibody Conjugate Technology: Near-infrared Photoimmunotherapy (PIT). PIT permits highly efficient and selective ablation of tumor cells while sparing damage to critical structures adjacent to the tumor.
Regulatory & Clinical Research Institute is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.